The Latest
-
Brian Tucker/BioPharma Dive
Deep DiveThe first coronavirus vaccines have arrived. Here's where the rest stand.
Crucial study results could come soon for vaccines being developed by Johnson & Johnson, AstraZeneca, Novavax and CureVac.
UPDATED: Jan. 14, 2021 at 11:11 a.m. -
Regeneron
US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug
The deal expands an earlier agreement between Regeneron and the U.S., though many of the issues limiting the drug's use haven't been solved.
-
Danielle Ternes / BioPharma Dive
JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's research and Pfizer's deep pockets
Verve, a buzzy gene editing startup, unveiled its first drug candidate, which is designed to treat hereditary high cholesterol by changing a single letter in the DNA sequence of a key gene.
-
Yujin Kim / BioPharma Dive
5 questions facing gene therapy in 2021
Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth. Dealmaking, however, appears to be continuing apace.
-
Danielle Ternes / BioPharma Dive
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.
-
Getty Images
Lilly rockets up on mixed Alzheimer's results
Analysts cautioned that results for Lilly's drug, donanemab, weren't a total home run. Even so, investors sent the company's market value higher by roughly $18 billion.
-
Danielle Ternes / BioPharma Dive
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
After disappointing results from a key study, Sarepta's CEO shared new data on its treatment for Duchenne muscular dystrophy.
-
5 FDA approval decisions to watch in the 1st quarter
Bristol Myers and Bluebird are awaiting an FDA decision on their multiple myeloma cell therapy ide-cel, and could also soon get news on their lymphoma CAR-T drug liso-cel.
-
Getty Images
Bluebird to split company, spin off cancer drug business
The high-profile biotech will separate into two independent, publicly traded companies in an attempt to revive its fortunes after several setbacks.
UPDATED: Jan. 11, 2021 at 2:18 p.m. -
Kendall Davis/BioPharma Dive
Record numbers of biotechs are going public. Here's how they're performing.
Cullinan Management and Gracell Biotechnologies raised about $460 million combined, adding to a string of IPO success for early-stage cancer drugmaker.
UPDATED: Nov. 13, 2020 at 9:57 a.m. -
Courtesy of BioMarin Pharmaceutical
BioMarin tries to get hemophilia gene therapy back on track with positive data
Full one-year results from a Phase 3 study show the therapy, known as Roctavian, sharply reduced bleeds and use of blood-clotting treatments.
-
Elizabeth Regan / Industry Dive
Celgene's cell therapy spinout nets $292M from blank-check merger
With additional financing, Celularity will have $372 million to back development of off-the-shelf treatments for cancer and autoimmune diseases.
-
Getty / Edited by BioPharma Dive
Sarepta gene therapy misses goal in key muscular dystrophy study
Company executives, however, blamed "improbably bad luck" for study enrollment that resulted in more older patients with milder disease receiving placebo, and pledged to press on.
-
Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial
Sarepta, though, may try to seek accelerated approval using Phase 2 data that's due imminently, along with results from another, smaller trial.
-
Courtesy of CureVac
Bayer partners with CureVac on coronavirus vaccine development
The German companies will work together to push a shot using similar technology as Moderna's and BioNTech's over the finish line.
-
Alnylam Pharmaceuticals
Alnylam, with positive data in hand, prepares to submit 4th drug for approval
Late-stage results for vutrisiran look as though they'll help Alnylam deliver on the promise that RNAi technology can be a repeatable drug platform.
-
Dollar Photo Club
Dewpoint forges another big pharma partnership — and a potential rivalry
The biotech, which works in the emerging research field of biomolecular condensates, is teaming up with Pfizer to find new treatments for a rare type of muscular dystrophy.
-
Courtesy of Roche
Roche adds to RNA drug deal streak with Ribometrix partnership
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.
-
Bayer AG
Leading $105M biotech funding, Bayer deepens cell therapy investment
A Series B investment in Senti Biosciences will support the startup's research on off-the-shelf candidates, as Bayer places another bet on cell therapy.
-
Danielle Ternes/BioPharma Dive
Dive Awards
The BioPharma Dive Awards for 2020
Vaccine developers and COVID-19 researchers took center stage in a year turned upside down by the pandemic.
-
Getty / Edited by BioPharma Dive
Biogen pushes further into eye gene therapy with new deal
Partnering with German biotech ViGeneron bolsters Biogen's pipeline of drugs for eye diseases, which includes assets acquired through its buyout of Nightstar Therapeutics.
-
Dollar Photo Club
A new, well-connected biotech aims to fight cancer with viruses
Founded by industry veteran Arie Belldegrun's venture capital firm, IconOVir Bio raised $77 million to push its lead drug — derived from the common cold — into clinical testing.
-
Permission granted by University of Maryland School of Medicine
FDA says changing coronavirus vaccine dosing could put 'public health at risk'
In an unusual statement, FDA chief Stephen Hahn and top official Peter Marks opposed altering vaccination regimens without further evidence, calling proposals to do so "premature."
-
Permission granted by Bristol-Myers Squibb
How an all-or-nothing bet on 3 Bristol Myers drugs came undone
With no decision from the FDA on approval of an experimental cancer cell therapy, an agreement by Bristol Myers to pay out more money as part of its Celgene acquisition fell apart.
-
Courtesy of BioNTech
Dive Awards
Vaccine Developers of the Year: BioNTech and Moderna
Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible.
